Business Context and Reporting Period
This Form 8-K is a current report filed by Hancock Jaffe Laboratories, Inc. (trading symbol HJLI) on February 18, 2021. The filing discloses executive compensation arrangements and stock option grants effective as of January 1, 2021, and February 18, 2021. Note: The input metadata references "Envveno Medical Corp," but the filing text explicitly identifies the registrant as Hancock Jaffe Laboratories, Inc.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary (CFO): $225,000 per year for Craig Glynn.
- Stock Option Exercise Price: $8.20 per share (closing price on February 18, 2021).
- Stock Option Grants:
- Craig Glynn (CFO): 324,000 shares.
- Robert Berman (CEO): 838,000 shares.
- Marc H. Glickman (CMO): 406,000 shares.
Material Changes
The primary material change is the appointment of Craig Glynn as full-time Chief Financial Officer, Treasurer, and Secretary, effective January 1, 2021. Additionally, the Board approved significant stock option grants for the CEO and CMO on February 18, 2021.
Guidance, Outlook, and Contingencies
Contingencies: All stock option grants described in this filing are contingent upon stockholder approval to increase the size of the Company's Amended and Restated 2016 Omnibus Incentive Plan. If stockholders do not approve the increase, the options will be void.
Vesting Schedules:
- CFO Options: Vest in equal quarterly installments over three years with a six-month cliff.
- CEO and CMO Options: Vest in equal quarterly installments over two years.
Severance Terms: In the event of termination without "Cause" or resignation for "Good Reason," the CFO is entitled to three months of severance for each year of employment, up to a maximum of one year of severance, plus accrued benefits.
Investor Verification Checklist
- Verify the outcome of the stockholder vote regarding the increase in the 2016 Omnibus Incentive Plan, as this determines the validity of the option grants.
- Confirm the exact vesting start dates and cliff periods for the new executive options.
- Review the full text of the Employment Agreement attached to the upcoming Form 10-K for detailed definitions of "Cause" and "Good Reason."
- Monitor the company's cash position to ensure it can support the new executive compensation structure.